Compare EVO & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | USPH |
|---|---|---|
| Founded | 1993 | 1990 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2021 | 1992 |
| Metric | EVO | USPH |
|---|---|---|
| Price | $3.65 | $81.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $106.50 |
| AVG Volume (30 Days) | ★ 251.6K | 190.5K |
| Earning Date | 11-05-2025 | 02-25-2026 |
| Dividend Yield | N/A | ★ 2.27% |
| EPS Growth | N/A | ★ 153.49 |
| EPS | N/A | ★ 2.38 |
| Revenue | ★ $887,396,457.00 | $750,948,000.00 |
| Revenue This Year | N/A | $19.53 |
| Revenue Next Year | $8.52 | $6.33 |
| P/E Ratio | ★ N/A | $33.44 |
| Revenue Growth | N/A | ★ 17.51 |
| 52 Week Low | $2.84 | $62.77 |
| 52 Week High | $4.80 | $93.50 |
| Indicator | EVO | USPH |
|---|---|---|
| Relative Strength Index (RSI) | 71.06 | 55.39 |
| Support Level | $3.10 | $78.61 |
| Resistance Level | $3.23 | $85.40 |
| Average True Range (ATR) | 0.08 | 3.31 |
| MACD | 0.08 | 0.11 |
| Stochastic Oscillator | 96.87 | 56.55 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.